← All Articles
Immune
Thymosin Alpha-1 and Immune Modulation
Irvine Health Editorial
2025-12-02
10 min read
Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymosin fraction 5 of bovine thymus tissue by Allan Goldstein and colleagues at the National Cancer Institute in the 1970s. It was among the first biologically active thymic peptides to be characterized and has since accumulated one of the most substantial clinical evidence bases of any therapeutic peptide, with approved use in multiple countries for hepatitis B, hepatitis C, and immune reconstitution in certain oncology contexts. A synthetic version (thymalfasin, trade name Zadaxin) has been approved in over 35 countries outside the United States.
Clinical Research
Hepatitis B — Chien et al., Hepatology (1998)
A randomized, double-blind, placebo-controlled trial of Thymosin Alpha-1 in chronic hepatitis B patients demonstrated a significantly higher rate of sustained viral response (loss of HBeAg and suppression of HBV DNA) in treated subjects versus placebo at 12-month follow-up. Combined therapy with interferon-alpha further improved response rates.
Hepatitis C — Sherman et al., Hepatology (1998)
In chronic hepatitis C, Tα1 combined with interferon-alpha produced higher rates of sustained response compared to interferon monotherapy. These trials established Tα1's role as an immune adjuvant in chronic viral hepatitis management in international markets.
Sepsis and Critical Illness — Shi et al., Intensive Care Med (2011)
A Chinese multicenter RCT of Thymosin Alpha-1 in severe sepsis patients found significantly lower 28-day mortality in the Tα1 group compared to controls (26.9% vs 35.4%). The authors proposed enhanced monocyte and dendritic cell function as the mechanism.
COVID-19 Research (2020–2021)
Multiple observational studies and pilot trials published during the COVID-19 pandemic investigated Tα1's potential role in immune modulation in critically ill patients. While preliminary data were promising, definitive RCT evidence remains limited, and this remains an active research area.
Mechanism of Action
Thymosin Alpha-1 acts on dendritic cells, T-lymphocytes, and natural killer cells. It appears to promote maturation of dendritic cell precursors, enhance toll-like receptor signaling, stimulate Th1 immune responses (cell-mediated immunity), and downregulate excessive Th2 responses in certain contexts. This dual immunomodulatory profile — stimulating deficient immune responses while potentially dampening harmful hyperinflammation — distinguishes it from simple immunostimulants.
Status in the United States
Thymosin Alpha-1 (thymalfasin) is not FDA-approved in the United States but is available as a compounded preparation through licensed 503A pharmacies with a physician prescription. Patients considering Tα1 therapy should have a thorough immune function evaluation and a clear clinical rationale established with their prescribing provider.
References
- Goldstein AL, et al. Thymosin alpha one: biological and clinical activity. Med Oncol Tumor Pharmacother. 1994;11(1):17-24.
- Chien RN, et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B. Hepatology. 1998;27(5):1383-7.
- Sherman KE, et al. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection. Hepatology. 1998;27(4):1128-35.
- Shi Y, et al. Thymosin alpha1 (Ta1) for severe sepsis: a multicenter, randomized, controlled trial. Intensive Care Med. 2011;37(3):444-52.
- Liu F, et al. Thymosin alpha-1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells. Clin Infect Dis. 2020;71(16):2150-2157.
Explore More Articles
Browse our full library of evidence-based peptide research.
View All Posts
*The assessment made available on the Irvine Health website does not create a doctor-patient relationship between the individual completing the assessment and Irvine Health. Irvine Health partners with a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety. The answers an individual provides to the Irvine Health assessment consequently determine if the individual is screened out of eligibility for medication, and an Irvine Health clinician will meet with an individual after checkout to determine if they qualify for a prescription. Irvine Health clinicians retain the decision to prescribe compounded medications to patients.
All claims and benefits on this website refer to self-reported data from customers on a treatment plan that includes compounded medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3–4 weeks thereafter. Results from compounded medications found on the Irvine Health platform may vary and be affected by an individual’s adherence to the program and their clinician’s recommendations. Compounded peptides and GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider’s medical judgment, which is informed by a telehealth consultation and medical history.
We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. Irvine Health does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.
Pharmacy Providers
We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.
*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs, and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.
Medication is included in the cost of the Irvine Health Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this Internet site are protected and belong to their respective owners. Medical treatment is provided by Irvine Health affiliated physicians and licensed professional corporations. No data, photos, claims, or any other information is associated with results derived from clinical trials, studies, or public information and is always representative of Irvine Health patient experience.
Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content.
© 2026 Irvine Health LLC. All rights reserved. 19200 Von Karman Avenue, 4th, 5th, and 6th Floors, Irvine, CA 92612.